Kristen Natalie Paolizzi, | |
210 Benigno Blvd, Bellmawr, NJ 08031-2514 | |
(856) 931-0691 | |
Not Available |
Full Name | Kristen Natalie Paolizzi |
---|---|
Gender | Female |
Speciality | Physician Assistant |
Location | 210 Benigno Blvd, Bellmawr, New Jersey |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1881277036 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363A00000X | Physician Assistant | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kristen Natalie Paolizzi, 31 Two Penny Run W, Pilesgrove, NJ 08098-2643 Ph: (856) 381-7878 | Kristen Natalie Paolizzi, 210 Benigno Blvd, Bellmawr, NJ 08031-2514 Ph: (856) 931-0691 |
News Archive
Medivance today announced the introduction of its next-generation therapeutic temperature management device, the non-invasive Arctic Sun 5000. The new patient cooling device has received FDA 510 (k) clearance and offers the fastest initiation of treatment, simplest programming capabilities and easiest access to treatment data on the market.
What makes some people more prone to wedded bliss or sorrow than others? Researchers at UC Berkeley and Northwestern University have found a major clue in our DNA. A gene involved in the regulation of serotonin can predict how much our emotions affect our relationships, according to a new study that may be the first to link genetics, emotions, and marital satisfaction. The study was conducted at UC Berkeley.
A University of Houston (UH) chemist who is developing materials for detecting and repelling E. coli has published papers in two high-impact journals this month.
Tiny, implantable computers that would restore brain function lost to disease or injury is the goal of University of Washington research recently funded by a $1 million, three-year grant from the W.M. Keck Foundation.
Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.
› Verified 3 days ago